Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation

Ann Hematol. 2019 Jan;98(1):237-240. doi: 10.1007/s00277-018-3427-1. Epub 2018 Jul 19.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Allografts
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / prevention & control*
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / therapy*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects
  • Middle Aged
  • Pilot Projects
  • Sirolimus / administration & dosage
  • Sirolimus / adverse effects
  • Survival Rate
  • Tacrolimus / administration & dosage
  • Tacrolimus / adverse effects
  • Unrelated Donors*

Substances

  • Sirolimus
  • Tacrolimus
  • Methotrexate